X0306 4 2022-06-08 0 0001620463 Athira Pharma, Inc. ATHA 0001822499 CHURCH KEVIN C/O ATHIRA PHARMA, INC. 18706 NORTH CREEK PARKWAY, SUITE 104 BOTHELL WA 98011 0 1 0 0 Executive VP, Research Common Stock 2022-05-18 5 A 0 E 243 7.06 A 47809 D Common Stock 2022-06-08 4 M 0 2500 1.35 A 50309 D Stock Option (Right to Buy) 1.35 2022-06-08 4 M 0 2500 0.00 D 2028-12-17 Common Stock 2500 10110 D The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Athira Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP Purchase Period (as defined in the ESPP) of November 18, 2021 through May 18, 2022. This transaction is also exempt under Rule 16b-3(c). The Purchase Period ended May 18, 2022 and is the Purchase Period comprising the Offering Period (as defined in the ESPP) that began November 18, 2021. In accordance with the ESPP, these shares were purchased based on 85% of the closing price on May 18, 2022. One-fourth of the shares subject to the option vested on January 1, 2020 and one-fourth of the shares subject to the option vest on each year thereafter. /s/ Glenna Mileson, Attorney-in-fact on behalf of Kevin Church 2022-06-10